Even with the relatively low sample numbers of these original studies, a clear trend was evident, ER was seen to be consistently activated by mutations in the ligand binding domain: a selection process that occurred in response to aromatase inhibitor treatment, highlighting the importance of using the most relevant samples.
← all excerpts
Why do we continue to have an incomplete understanding of estrogen receptor(s) actions in cancer systems?
1
—
—